Adam Ressler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adam Ressler has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anurag Malani
Division of Infectious Diseases, Department of Internal Medicine, Trinity Health Michigan , Ann Arbor, Michigan , USA
1 shared publication Brenda M Brennan
Michigan Department of Health and Human Services , Lansing, Michigan
1 shared publication- Catherine M. Jankowski
College of Nursing, University of Colorado-Anschutz, Aurora, CO; and
1 shared publication Elisia Stier
Michigan Department of Health and Human Services , Lansing, Michigan
1 shared publication- Jason M. Pogue
Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI
1 shared publication - Joseph Coyle
Michigan Department of Health and Human Services , Lansing, Michigan
1 shared publication
Latest Publications
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience
Candida auris is an emerging fungal pathogen with high rates of morbidity and mortality. In May 2021, the Michigan Department of Health and Human Services (MDHHS), detected its first case of Candida auris and has since seen a rapid increase in southeast MI. There is currently no C. auris screening guidance developed for states. MDHHS Surveillance for Healthcare Associated and Resistant Pathogens (SHARP) Unit convened a multidisciplinary group from acute care facilities to collaborate on the development of guidance to rapidly assess, screen, and isolate patients entering healthcare facilities in efforts to slow the spread of C. auris. The MDHHS SHARP Unit invited individuals representing infection prevention, infectious diseases, antimicrobial stewardship/pharmacy, lab, and epidemiology to participate. The purpose was to engage healthcare partners by providing updates on epidemiology, surveillance, antifungal susceptibilities, lab capacity, and containment/prevention activities in the state. Facilities were able to share best-practices and collaborate with public health to develop pragmatic recommendations that could be implemented within facilities across the region. MDHHS collaborated with healthcare partners to develop C. auris screening guidance that is evidence-based, easy-to-reference, and adaptable across facility-types. Previous regional approaches, such as the Michigan CRE Surveillance and Prevention Initiative, have proven to be substantially more effective at stemming the spread of multidrug resistant organisms. Michigan will continue these successful collaborations and apply this approach for future emerging pathogens. jason M. Pogue, PharmD, AbbVie: Advisor/Consultant|Entasis: Advisor/Consultant|Ferring: Advisor/Consultant|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Qpex: Advisor/Consultant|Shionogi: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience
Candida auris is an emerging fungal pathogen with high rates of morbidity and mortality. In May 2021, the Michigan Department of Health and Human Services (MDHHS), detected its first case of Candida auris and has since seen a rapid increase in southeast MI. There is currently no C. auris screening guidance developed for states. MDHHS Surveillance for Healthcare Associated and Resistant Pathogens (SHARP) Unit convened a multidisciplinary group from acute care facilities to collaborate on the development of guidance to rapidly assess, screen, and isolate patients entering healthcare facilities in efforts to slow the spread of C. auris. The MDHHS SHARP Unit invited individuals representing infection prevention, infectious diseases, antimicrobial stewardship/pharmacy, lab, and epidemiology to participate. The purpose was to engage healthcare partners by providing updates on epidemiology, surveillance, antifungal susceptibilities, lab capacity, and containment/prevention activities in the state. Facilities were able to share best-practices and collaborate with public health to develop pragmatic recommendations that could be implemented within facilities across the region. MDHHS collaborated with healthcare partners to develop C. auris screening guidance that is evidence-based, easy-to-reference, and adaptable across facility-types. Previous regional approaches, such as the Michigan CRE Surveillance and Prevention Initiative, have proven to be substantially more effective at stemming the spread of multidrug resistant organisms. Michigan will continue these successful collaborations and apply this approach for future emerging pathogens. jason M. Pogue, PharmD, AbbVie: Advisor/Consultant|Entasis: Advisor/Consultant|Ferring: Advisor/Consultant|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Qpex: Advisor/Consultant|Shionogi: Advisor/Consultant
- Open Access
- 13 February 2020
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 32 (1) , 127-133
End-of-Life Planning Prior to Death Among People Living With HIV
People with HIV (PWH) often experience social isolation, loss of friends or partners, and estranged family relationships, creating challenges in selecting medical decision makers or clarifying end-of-life wishes. Whether advanced directive (AD) completion rates or informal proxy or medical power assignment (MPOA) differ by ultimate cause of death is unknown. We conducted a retrospective study of deceased PWH from a single clinic to examine factors associated with AD completion (47%) or MPOA assignment (73%) prior to death. AD completers were older at death (54.3[10.9] vs. 50.3[11.1] years, p = .04) than non-completers, and cancer death was more prevalent (23[54%] vs. 9[22%], p = .014). Patients with an MPOA had lower CD4 count (48% vs. 21%) and greater prevalence of cancer death (48% vs. 15%), but were of similar age at death (51.9[11.2] vs. 52.9[11.2] years, p = .66). This research identifies target populations for AD or MPOA education and assistance.
- 13 February 2020
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 32 (1) , 127-133
Open AccessEnd-of-Life Planning Prior to Death Among People Living With HIV
People with HIV (PWH) often experience social isolation, loss of friends or partners, and estranged family relationships, creating challenges in selecting medical decision makers or clarifying end-of-life wishes. Whether advanced directive (AD) completion rates or informal proxy or medical power assignment (MPOA) differ by ultimate cause of death is unknown. We conducted a retrospective study of deceased PWH from a single clinic to examine factors associated with AD completion (47%) or MPOA assignment (73%) prior to death. AD completers were older at death (54.3[10.9] vs. 50.3[11.1] years, p = .04) than non-completers, and cancer death was more prevalent (23[54%] vs. 9[22%], p = .014). Patients with an MPOA had lower CD4 count (48% vs. 21%) and greater prevalence of cancer death (48% vs. 15%), but were of similar age at death (51.9[11.2] vs. 52.9[11.2] years, p = .66). This research identifies target populations for AD or MPOA education and assistance.